4d Molecular Therapeutics, Inc.
A maker of genetic medicines, 4D Molecular Therapeutics engineers custom viral delivery vehicles to treat diseases of the eye, lung, and heart. Founded in 2013 by a UC Berkeley professor and a biotech entrepreneur who met at a university innovation hub, the company got its start in a garage incubator. Its name reflects the four dimensions of optimization its scientists pursue when designing the adeno-associated virus vectors that carry therapeutic genes into the body.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | 13G/APassive | 9.99% | 5.35M | May 15, 2026 |
| BVF INC/IL | 13G/APassive | 9.99% | 5.35M | May 15, 2026 |
| LAMPERT MARK N | 13G/APassive | 9.99% | 5.35M | May 15, 2026 |
| RA Capital Management, L.P. | 13G/APassive | 9.9% | 5.11M | May 15, 2026 |
| Peter Kolchinsky | 13G/APassive | 9.9% | 5.11M | May 15, 2026 |
| Rajeev Shah | 13G/APassive | 9.9% | 5.11M | May 15, 2026 |
| RA Capital Healthcare Fund, L.P. | 13G/APassive | 9.9% | 5.11M | May 15, 2026 |
| BVF GP HOLDINGS LLC | 13G/APassive | 9.3% | 5.00M | May 15, 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 13G/APassive | 7.3% | 3.91M | May 15, 2026 |
| BVF I GP LLC | 13G/APassive | 7.3% | 3.91M | May 15, 2026 |